{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045022","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.280170+00:00","generated_at":"2026-05-30T06:11:01.225054+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbCellera Q3 net loss widens to $51.1M as expenses rise; revenue flat at $6.5M","bullets":["Revenue $6.5M, flat QoQ and YoY; net loss $51.1M ($0.17/share) vs $28.6M ($0.10/share) in Q3 2023.","R&D expenses rose to $41.0M from $37.9M; G&A expenses increased to $19.1M from $14.4M.","Cumulative partner programs with downstreams reached 95 (up 13% YoY); molecules in clinic grew to 14 from 10.","Expanded Lilly collaboration into immunology, cardiovascular, neuroscience; completed Vancouver HQ consolidation.","Total liquidity over $875M ($670M cash + $205M government funding)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045022","json":"https://secwatch.observer/filing/0001628280-24-045022.json","markdown":"https://secwatch.observer/filing/0001628280-24-045022.md","text":"https://secwatch.observer/filing/0001628280-24-045022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000162828024045022/0001628280-24-045022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000162828024045022/abcl-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:11:01.225054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}